Genes obtained after transcriptome-wide association study mapped to QTL regions related to percentage of fiber types I, IIA, and IIB I fiber type SSC QTL ID SCRN2 12 2819 2821 UTP18 2819 2821 TOM1L1 2819 2821 WRAP53 2819 2821 FASTKD1 15 2832 HNRNPA3 2832 IIA fiber type SSC QTL ID SLF1 2 2797 CAST 2797 ANAPC7 14 7018 PPTC7 7018 AP1B1 7018 MTR 7018 ARV1 7018 RAB4A 7018 SUPV3L1 7018 FAM45A 2827 TACC2 2827 PAF1 2827 IIB fiber type SSC QTL ID RGP1 1 2795 IKBKAP 2795 TTL 3 7037 UXS1 7037 IL1R1
7037 MAP4K4 7037 NAGK 7037 PCYOX1 7037 EFEMP1 7037 MTIF2 7037 FEZ2 7037 CRIM1 7037 HDGF 4 2807 2810 PAQR6 2807 2810 RFX5 2807 2810 ANAPC7 14 7038 PPTC7 7038 AP1B1 7038 MTR 7038 ARV1 7038 RAB4A 7038 SUPV3L1 7038 FAM45A 2828 TACC2 2828 PAF1 2828 QTL, quantitative trait loci; SSC, chromosome 2.
TLR4 antagonism by CyP was effective in delaying seizure onset and in reducing recurrence in an acute model of seizure; the treatment with CyP in combination with a drug targeting IL1R1
(VX-765) after epilepsy onset in a chronic mice model prevented disease progression and drastically reduced chronic seizure recurrence .
Interleukins [interleukin 8 (IL8), interleukin 6 signal transducer (IL6ST), interleukin 7 (IL7), interleukin 15 (IL15), and interleukin 1 receptor type 1 (IL1R1
)] and chemokines [C-X-C motif chemokine ligand 2 (CXCL2), C-X-C motif chemokine ligand 6 (CXCL6), C-X-C motif chemokine ligand 10 (CXCL10), C-X-C motif chemokine ligand 11 (CXCL11), C-C motif chemokine ligand 5 (CCL5), and C-C motif chemokine ligand 28 (CCL28)] also were overexpressed in HT-29 cells.
Where indicated, cultures were incubated in the following primary antibodies: 11[beta]-HSD2 (1: 250; Santa Cruz), AcH3 (1: 250; Santa Cruz), GR (1: 250; Santa Cruz), or IL1R1
(1:250; Invitrogen) diluted in 1% BSA in 10 mM PBS at 4[degrees]C for 16 h.
Pathways Number of Involved Adjusted hits genes p value Pathways in 9 Jun, Runx1, MAX, Fas, 0.005 cancer FGF22, HSP90AA2, Cdk2, ETS1, Cdc42 MAPK signaling 7 Jun, MAX, Fas, FGF22, 0.024 pathway mapt, Il1r1
, Cdc42 GnRH signaling 4 Jun, ITPR2, Gnas, Cdc42 0.049 pathway
Module Drug Drug Drug class target (2) JAK1 Tofacitinib DMARDs JAK2 Tofacitinib DMARDs (4) IL1B Canakinumab Biotech agents IL6R Tocilizumab Biotech agents LTA Etanercept Biotech agents Etanercept Biotech agents Adalimumab Biotech agents TNF Infliximab Biotech agents Golimumab Biotech agents Certolizumab pegol Biotech agents Chloroquine DMARDs TNFRSF1B Etanercept Biotech agents (5) IL1R1
Anakinra Biotech agents (6) PTK2B Leflunomide DMARDs (7) MAPK3 Sulindac NSAIAs CHUK Sulfasalazine DMARDs (8) IKBKB Sulfasalazine DMARDs Auranofin DMARDs (9) PDPK1 Celecoxib NSAIAs (10) BCL2 Ibuprofen NSAIAs
IL1RAP is part of a membrane bound receptor complex with IL-1 receptor type 1 (IL1R1
) that recognizes the proinflammatory cytokine IL-1[beta].
Allelic variants of IL1R1
gene associate with severe hand osteoarthritis.
Pastorelli et al., "Associations between genetic polymorphisms in IL-33, IL1R1
and risk for inflammatory bowel disease," PLoS One, vol.
However, regardless of the photoperiod, endotoxin treatment stimulated (p<0.05) expression of the genes encoding interleukin (IL) -1 receptor 1 (IL1R1
), IL1R2 and glycoprotein 130 (IL6ST), which are necessary for the transduction of IL-6R signals.
Among them, IL1R1
and a-tocopherol transfer protein have been reported to affect the pathology of AAA.
The top distinctive genes for the proliferation metaprofile include, besides previously used markers, numerous genes related to malignancy and ovarian cancer progression, in particular cytokines and their receptors: CXCL1, IL1A, CXCL8, IL1B, IL1R1
, and IL1R2 [19-22].